Gyros AB

Gyros AB is a biotechnology company focused on enhancing biotherapeutic development through advanced peptide synthesis and automated immunoassay solutions, delivering high sensitivity and efficiency in biomarker analysis. Founded in 2000 in Uppsala, Sweden, Gyros AB specializes in automated immunoassays and peptide synthesis. The company has participated in three funding deals, including a Series C round in July 2009, raising USD 10. 4 mn led by SLS Invest.

The company operates globally but is based in Uppsala, Sweden. Gyros Protein Technologies specializes in advanced peptide synthesis and immunoassay solutions aimed at accelerating biotherapeutic development. Their core offerings include the Gyrolab platform for automated immunoassays, which enhances biomarker quantification through minimal sample usage and high sensitivity, and the PurePep technology for peptide synthesis that addresses productivity challenges in research. These products are designed for use in various applications, including biomarker monitoring, pharmacokinetics studies, and the production of peptides for therapeutics and vaccines.

The company serves a diverse client base that includes biopharmaceutical companies, contract research organizations (CROs), and academic institutions across key geographical markets such as North America, Europe, and Asia. Gyros Protein Technologies generates revenue through direct sales of its immunoassay and peptide synthesis products, as well as through custom assay development and related services. The company engages in B2B transactions, primarily catering to laboratories and research institutions that require specialized biomolecular analysis tools. Typical business transactions involve the sale of Gyrolab systems and consumables, along with service contracts for technical support and maintenance.

Revenue is structured around the initial sale of equipment, with recurring income from the sale of consumables and service agreements. Their flagship products, such as the Gyrolab platform and PurePep synthesizers, are central to their revenue model, enabling clients to enhance their research capabilities while ensuring high-quality outputs in biotherapeutic development. Gyros AB plans to utilize the USD 10. 4 mn raised in its Series C round to develop new products and expand its market presence.

The company is focused on designing innovative solutions that cater to the evolving needs of the biotherapeutic sector. Additionally, Gyros aims to expand its operations into new geographical regions, particularly targeting growth in Asia and North America by 2025.